Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

Condition:   VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
Interventions:   Drug: JNJ-64179375 0.3 mg/kg;   Drug: JNJ-64179375 0.6 mg/kg;   Drug: JNJ-64179375 1.2 mg/kg;   Drug: JNJ-64179375 (Dose to be Determined);   Drug: JNJ-64179375 A mg/kg;   Drug: JNJ-64179375 B mg/kg;   Drug: JNJ-64179375 C mg/kg;   Drug: JNJ-64179375 D mg/kg;   Drug: Placebo JNJ-64179375;   Drug: Apixaban placebo;   Drug: Apixaban 2.5 mg
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified August 2017

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Conditions:   Venous Thromboembolism;   Deep Vein Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Tinzaparin
Sponsor:   The University of Hong Kong
Not yet recruiting - verified August 2017

Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

Conditions:   Venous Thromboembolism;   Deep Venous Thrombosis;   Pulmonary Embolus;   Reconstructive Surgery
Interventions:   Drug: Enoxaparin;   Drug: Enoxaparin
Sponsors:   University of Utah;   Stanford University
Recruiting - verified August 2017

Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT

Conditions:   Acute Kidney Injury;   Pulmonary Embolism;   Contrast-induced Nephropathy
Interventions:   Diagnostic Test: V/Q imaging;   Diagnostic Test: Computed tomography scan
Sponsors:   Indiana University;   National Institutes of Health (NIH)
Recruiting - verified August 2017

Validation of Epworth Richmond's Echocardiography Education Focused Year

Conditions:   Shock, Cardiogenic;   Cardiac Tamponade;   Pulmonary Embolism;   Hypovolemia
Intervention:   Behavioral: Epworth Richmond's Echocardiography Focused Year
Sponsors:   Epworth Healthcare;   University of Melbourne
Completed - verified August 2017

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified August 2017

Standard vs. Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism

Condition:   Pulmonary Embolism
Interventions:   Procedure: CDT without ultrasound acceleration;   Procedure: CDT with ultrasound acceleration
Sponsor:   University of Pittsburgh
Recruiting - verified August 2017

Dedicated Ambulator-assisted Physical Activity to Improve Hospital Outcome Measures in Elderly Patients

Conditions:   Weakness;   Hospital Acquired Condition
Intervention:   Other: Ambulation
Sponsor:   The Cleveland Clinic
Completed - verified August 2017

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Condition:   Venous Thromboembolism
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive

Condition:   Pulmonary Embolism
Interventions:   Drug: Furosemide;   Drug: NaCl 9% isotonic
Sponsor:   Centre Hospitalier Universitaire de Nice
Recruiting - verified August 2017

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified August 2017

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified August 2017

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2017

Normoglycemia and Neurological Outcome

Conditions:   Acute, Non-traumatic Subarachnoid Hemorrhage;   Intraparenchymal Hemorrhage;   Brain Injuries
Interventions:   Drug: Insulin;   Drug: Conventional insulin treatment
Sponsor:   University of Louisville
Terminated - verified August 2017